J Korean Fract Soc.  2021 Oct;34(4):148-153. 10.12671/jkfs.2021.34.4.148.

Romosozumab: A Novel Agent in the Management of Osteoporosis

• Moon NH
• Shin WC
• Jang JH

• KMID: 2521506
• DOI: http://doi.org/10.12671/jkfs.2021.34.4.148

Abstract

With the discovery of screlostin as a pivotal player in bone metabolism, a novel medication targeting sclerostin has been introduced. Romosozumab, a humanized anti-sclerostin monoclonal antibody, is a unique approach to the treatment of osteoporosis that inhibits sclerostin, a key regulator that has the dual properties of promoting bone formation and inhibiting bone resorption. Romosozumab has been shown to be superior to conventional agents, in increasing bone mineral density and preventing osteoporotic fractures. Romosozumab may also be effective in the management of treatment-resistant osteoporosis and in the prevention of osteoporotic fractures in the very high risk population. However, further studies are necessary as there is insufficient data on its clinical efficacy and safety.

Keyword

Romosozumab; Osteoporosis